enfortumab vedotin sold brand name padcev antibodydrug used treatment urothelial antibody microtubule inhibitor enfortumab refers monoclonal antibody part vedotin refers payload drug mmae common side effects include fatigue peripheral neuropathy nerve damage resulting tingling numbness decreased appetite rash alopecia hair loss nausea altered taste diarrhea dry eye pruritus itching dry fully humanized antibody created scientists agensys part astellas using xenomice amgen linker technology holding antibody toxin together provided licensed seattle us food drug administration fda considers firstinclass enfortumab vedotin indicated treatment adults locally advanced cancer grown large surgically removed metastatic cancer cells spread parts body urothelial cancer previously received programmed death programmed death ligand inhibitor platinumcontaining results phase clinical trial reported december enfortumab vedotin approved united states treatment adult patients locally advanced metastatic urothelial cancer previously received programmed cell death programmed death ligand inhibitor platinumcontaining enfortumab vedotin approved based results clinical trial enrolled patients locally advanced metastatic urothelial cancer received prior treatment inhibitor platinumbased overall response rate reflecting percentage patients certain amount tumor shrinkage complete response partial median duration response us food drug administration fda granted application enfortumab vedotin accelerated approval priority review designation breakthrough therapy fda granted approval padcev astellas pharma us july fda approved enfortumab vedotin adults locally advanced metastatic urothelial cancer previously received programmed death programmed deathligand inhibitor platinumcontaining chemotherapy ineligible cisplatincontaining chemotherapy previously received one prior lines december february committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product padcev intended treatment adults urothelial applicant medicinal product astellas pharma europe enfortumab vedotin approved medical use european union april enfortumab vedotin international nonproprietary name united states adopted name httpsenwikipediaorgwikienfortumabvedotin